Form 4: Lexeo Therapeutics Insider Sells Shares
Statement of Changes in Beneficial Ownership
Lexeo Therapeutics' Chief Financial Officer, Louis Edward Tamayo, reported a sale of 4,641 shares of common stock on July 1, 2026, for a weighted average price of $4.49 per share.
Summary
- Louis Edward Tamayo, Chief Financial Officer of Lexeo Therapeutics, Inc., acquired 12,000 shares of common stock on June 29, 2026, at no cost.
- On July 1, 2026, Tamayo sold 4,641 shares of common stock at a weighted average price of $4.49 per share.
- This sale was conducted to cover tax obligations related to the release of performance Restricted Stock Units (RSUs).
- Following these transactions, Tamayo beneficially owns 97,024 shares of common stock, which includes 89,665 RSUs.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as the reported transactions are standard insider activity related to compensation and tax obligations, rather than a reflection of the company's fundamental performance or strategic direction.
Positives
- Acquisition of 12,000 shares of common stock at no cost on June 29, 2026.
- Retention of a significant number of shares (97,024) after the reported sale, indicating continued ownership.
Negatives
- Sale of 4,641 shares of common stock on July 1, 2026, at a weighted average price of $4.49 per share.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it pertains to insider stock transactions.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider stock transactions, providing transparency into executive compensation and potential shifts in insider confidence. The sale by the CFO to cover tax obligations on RSUs is a common occurrence.
Stakeholder Impact
- Shareholders: The sale of shares by a key executive may be monitored, but the stated reason (tax obligations on RSUs) suggests it is not indicative of a negative view on the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 06/29/2026 | Earliest transaction date; Acquisition of 12,000 shares of Common Stock. |
| 07/01/2026 | Sale of 4,641 shares of Common Stock to cover tax obligations. |
Keywords
Form 4, Insider Transaction, Lexeo Therapeutics, Louis Edward Tamayo, Chief Financial Officer, Common Stock, Restricted Stock Units, Sale of Shares, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.